Erin White
Acute Care · Richmond, VANPI 1386166288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,580 and has fallen 55.9% since, to $697 in 2025. Among acute care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$763
- Novartis$609
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$433
- Amgen$392
- Abbott$342
- Merck$232
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,88099%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $763 |
| Novartis | 31 | $609 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $433 |
| Amgen | 16 | $392 |
| Abbott | 5 | $342 |
| Merck | 14 | $232 |
| E.r. Squibb & Sons, L.L.C. | 14 | $209 |
| Boston Scientific | 7 | $183 |
| Baxter Healthcare | 6 | $173 |
| Actelion Pharmaceuticals US, Inc. | 5 | $160 |
| Novo Nordisk | 6 | $135 |
| Pfizer | 8 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $119 |
| Johnson & Johnson | 6 | $112 |
| Boehringer Ingelheim | 4 | $91 |
| Scpharmaceuticals Inc. | 5 | $90 |
| W. L. Gore & Associates, Inc. | 1 | $81 |
| Inspire Medical Systems, Inc. | 3 | $78 |
| Edwards Lifesciences | 3 | $59 |
| Irhythm Technologies, Inc. | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $58 |
| Medicomp Inc | 2 | $55 |
| Kestra Medical Technology Services, Inc. | 2 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Atricure, Inc. | 1 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Philips North America LLC | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Medtronic | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$357
- MitraClip System$142
- Repatha$113
How this compares
$4,950 in reported general payments places this provider in the 90th percentile of 599 acute care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $229,856 |
| EntrestoSacubitril/Valsartan | 52 | $45,821 |
| XareltoRivaroxaban | 35 | $44,466 |
| FarxigaDapagliflozin Propanediol | 35 | $26,246 |
| Metoprolol Succinate | 239 | $3,518 |
| Digoxin | 21 | $2,562 |
| Rosuvastatin Calcium | 187 | $1,974 |
| Atorvastatin Calcium | 173 | $1,717 |
| Bumetanide | 30 | $1,670 |
| Amlodipine Besylate | 234 | $1,430 |
| Ranolazine ErRanolazine | 14 | $1,301 |
| Potassium Chloride | 58 | $1,034 |
| Amiodarone Hcl | 50 | $984 |
| Valsartan | 37 | $930 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 41 | $923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $229,856244 claims |
| NovartisEntresto | $609 | $45,82152 claims |
| Johnson & JohnsonXarelto | $112 | $44,46635 claims |
| AstraZenecaFarxiga | $763 | $26,24635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 acute care providers in Virginia.
Other acute care in Richmond
- Rachel DukeRichmond$751K
- Mica FerlisRichmond$20K
- Jonathan PenderRichmond$13K
- Erin PerlmutterRichmond$13K
- Emily GilbertRichmond$10K
- Linda HazelgrenRichmond$9K
- Stephanie HerndonRichmond$9K
- Christine RobinsonRichmond$8K
- Kelly McAdamsRichmond$7K
- Linda KashiwabaraRichmond$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.